Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Scope
The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided
Key Highlights
Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain
Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)
Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time
Reasons to Buy
Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts
Akarna Therapeutics
Akero Therapeutics
Albireo
Allergan
Allergan (acquired from
Ardelyx
Arisaph
AstraZeneca
BHV Pharma Inc
Bird Rock Bio/Janssen
BMS
Boehringer Ingelheim
Can-Fite BioPharma
Celgene
Cempra
Cerenis Therapeutics
ChemomAb
Cirius Therapeutics
CohBar
ConSynance Therapeutics
CymaBay Therapeutics
DeuteRx
Dr. Falk Pharma GmbH
DURECT Corporation
Eli Lilly
Enanta
Galectin Therapeutics
Galmed
Gemcabene
Genfit
Gilead
GRI Bio
HighTide Biopharma
Immune Pharmaceuticals Inc.
Immuron
Intercept
INVENT Pharmaceuticals
Inventiva
Ionis Pharma-ceuticals
Janssen
Madrigal
MediciNova
Metacrine
Mitsubishi Tanabe
Naia
NGM Biopharmaceuticals
Nitto Denko
NorthSea Therapeutics
Novartis
Novo Nordisk
NuSirt BioPharma
Oramed
Pfizer
Poxel
Sanofi
Second Genome
Shire
Sinew Pharma
Sucampo Pharmaceuticals
Synairgen
Taiwan Pharmaceuticals
Teva
Tiziana Life Sciences
Valbiotis
Viking Therapeutics
Virobay
Zafgen
Zydus Discovery
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.